Latest News

Monday 30 March 2015: Medical News Today features article on Hexvix fluorescence-guided bladder resection: Recently published data demonstrate favorable overall survival outcome in bladder cancer patients

Hexvix blue-light flexible cystoscopy allows for better identification and management of recurrent low-grade tumors in the outpatient setting, providing clinical, patient, and economic benefits.

Oslo, Norway, 12 March 2015: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, is pleased to announce that a study published in Scandinavian Journal of Urology concludes that fluorescence cystoscopy with Hexvix® and immediate post-transurethral resection of the bladder (TURB) chemoprophylaxis effectively reduced the recurrence risk and the number of follow-up TURB procedures under clinical routine conditions.

Oslo, Norway, 2 March 2015: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, is pleased to announce that the National Institute for Health and Care Excellence (NICE) in the UK has published its first guidelines on bladder cancer, recommending photodynamic diagnosis for improved detection of bladder cancer.(1) NICE makes evidence-based recommendations for healthcare, with the aim of improving treatment and reducing variations in care.

Oslo, Norway, 12 February 2015: Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces its results for fourth quarter and full year 2014.

In a retrospective study Hexvix fluorescence–guided bladder resection significantly improved overall survival and recurrence free survival compared to resection performed with standard white light.

Cevira® advances towards Phase 3 for treatment in patients with cervical high-grade lesions (HSIL)

Kjetil Hestdal, President and CEO of Photocure, has today, December 23th 2014, exercised 37 500 share options in Photocure ASA, at the strike price of NOK 18.30.

Review article highlights Cevira® as a promising tissue sparing alternative to observation and surgical procedures in patients with cervical precancerous lesions

US Nurses’ perspectives on successful implementation of blue-light cystoscopy published in the AORN Journal (November 2014)

“Photodynamic Diagnosis of the Urinary Bladder using Flexible Instruments –Ready for the Outpatient Setting?”

Oslo, Norway, 6 November 2014: Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces its results for third quarter and the first nine months 2014.

Phase 2b results demonstrate significant and sustained efficacy in treating human papilloma virus and precancerous lesions of the cervix.

Cevira® was recently presented in the Nolato Magazine no 25. Oct 2014.

The results of the Cevira Phase 2b were presented 10.10.2014 at the annual German gynecology meeting (DGGG) in Munich, one of the key gynecology conferences in Europe with nearly 2000 participants.